Multiparametric Total-Body [18F]F-AraG PET/CT Imaging in Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)

Publication date: Jul 10, 2025

This study uses total-body [^1⁸F]F-AraG PET/CT imaging to investigate immune activation and vascular changes in individuals with post-acute sequelae of SARS-CoV-2 infection (PASC), also known as Long COVID. Participants will undergo dynamic PET/CT imaging along with blood biomarker assessments and symptom evaluations. The study aims to characterize sites of immunological perturbation, correlate PET imaging findings with peripheral blood markers, and evaluate longitudinal changes in tissue-based immune activity in relation to symptom patterns over time. Data from this study will improve understanding of tissue-level immune dysregulation in PASC and support future clinical tools for assessing and managing this condition.

Concepts	Keywords
California	Acute
Claustrophobia	Body
Immunophenotyping	Cov
Principal	Covid
	Ct
	Imaging
	Immune
	Infection
	Months
	Participants
	Pasc
	Pet
	Post
	Sars
	Symptom

Semantics

Type	Source	Name
disease	MESH	Post-Acute Sequelae of SARS-CoV-2 Infection
pathway	REACTOME	SARS-CoV-2 Infection
disease	IDO	infection
disease	IDO	blood
disease	IDO	symptom
disease	MESH	SARS-CoV-2 infection
disease	IDO	nucleic acid
drug	DRUGBANK	Creatinine
disease	MESH	relapse
pathway	REACTOME	Immune System
disease	MESH	immune disorders
disease	MESH	malignancy
disease	MESH	viral infections
disease	MESH	hepatitis B
pathway	KEGG	Hepatitis B
disease	MESH	hepatitis C
pathway	KEGG	Hepatitis C
drug	DRUGBANK	Chorionic Gonadotropin (Human)
disease	IDO	cell
disease	MESH	syndrome
disease	IDO	history
disease	MESH	autoimmune diseases
disease	MESH	anxiety
disease	MESH	claustrophobia
drug	DRUGBANK	Guanosine
drug	DRUGBANK	L-Cysteine

Original Article

(Visited 2 times, 1 visits today)